| 发明名称 |
B-cell reduction using cd37-specific and cd20-specific binding molecules |
| 摘要 |
<p>Disclosed is the use of one or more CD37-specific binding proteins in the manufacture of a composition for treating a disease or disorder associated with aberrant B cell activity, wherein the composition is to be administered in combination with rituximab.</p> |
| 申请公布号 |
NZ606294(A) |
申请公布日期 |
2014.09.26 |
| 申请号 |
NZ20060606294 |
申请日期 |
2006.07.25 |
| 申请人 |
EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC |
发明人 |
JEFFREY A. LEDBETTER;MARTHA SUSAN HAYDEN-LEDBETTER;WILLIAM BRADY;PETER ARMSTRONG THOMPSON;SANDY ALEXANDER SIMON;LAURA SUE GROSMAIRE |
| 分类号 |
C12N5/10;A61K39/395;A61P21/04;A61P35/00;A61P37/00;C07K16/28;C07K16/46;C12N15/13;C12N15/85 |
主分类号 |
C12N5/10 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
